ITCI
Intra-Cellular Therapies Inc
Halal Rating :
Last Price
$126.19
Last updated:
Market Cap
-
7D Change
-0.79%
1 Year Change
87.44%
Company Overview
Industries
Exchange
Next Earnings Date
Intra-Cellular Therapies Inc is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of central nervous system (CNS) disorders. Their lead product, CAPLYTA® (lumateperone), is approved for the treatment of schizophrenia in adults and bipolar depression. The company continues to research and develop novel therapeutic compounds for neurological and psychiatric conditions.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $175.38m | $214.22m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $161.39m | $189.11m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $144.87m | $165.82m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Intra-Cellular Therapies Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.